303 related articles for article (PubMed ID: 25902530)
1. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.
Ebert G; Allison C; Preston S; Cooney J; Toe JG; Stutz MD; Ojaimi S; Baschuk N; Nachbur U; Torresi J; Silke J; Begley CG; Pellegrini M
Proc Natl Acad Sci U S A; 2015 May; 112(18):5803-8. PubMed ID: 25902530
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo.
Morrish E; Mackiewicz L; Silke N; Pellegrini M; Silke J; Brumatti G; Ebert G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32824616
[TBL] [Abstract][Full Text] [Related]
3. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.
Ebert G; Preston S; Allison C; Cooney J; Toe JG; Stutz MD; Ojaimi S; Scott HW; Baschuk N; Nachbur U; Torresi J; Chin R; Colledge D; Li X; Warner N; Revill P; Bowden S; Silke J; Begley CG; Pellegrini M
Proc Natl Acad Sci U S A; 2015 May; 112(18):5797-802. PubMed ID: 25902529
[TBL] [Abstract][Full Text] [Related]
4. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
5. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
6. Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models.
Clark MP; Huynh T; Rao S; Mackiewicz L; Mason H; Romal S; Stutz MD; Ahn SH; Earnest L; Sozzi V; Littlejohn M; Tran BM; Wiedemann N; Vincan E; Torresi J; Netter HJ; Mahmoudi T; Revill P; Pellegrini M; Ebert G
Cell Death Dis; 2021 Jun; 12(7):641. PubMed ID: 34162831
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis: After HCV cure, HBV cure?
Lucifora J; Trepo C
Nat Rev Gastroenterol Hepatol; 2015 Jul; 12(7):376-8. PubMed ID: 26100368
[TBL] [Abstract][Full Text] [Related]
8. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
9. SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells.
Campbell GR; Bruckman RS; Chu YL; Trout RN; Spector SA
Cell Host Microbe; 2018 Nov; 24(5):689-702.e7. PubMed ID: 30344003
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
[TBL] [Abstract][Full Text] [Related]
11. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
12. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
Liu H; Liao R; He K; Zhu X; Li P; Gong J
Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
[TBL] [Abstract][Full Text] [Related]
13. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.
Kearney CJ; Lalaoui N; Freeman AJ; Ramsbottom KM; Silke J; Oliaro J
Cell Death Differ; 2017 Oct; 24(10):1705-1716. PubMed ID: 28665401
[TBL] [Abstract][Full Text] [Related]
16. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HBV replication by theophylline.
Zheng Z; Li J; Sun J; Song T; Wei C; Zhang Y; Rao G; Chen G; Li D; Yang G; Han B; Wei S; Cao C; Zhong H
Antiviral Res; 2011 Feb; 89(2):149-55. PubMed ID: 21167867
[TBL] [Abstract][Full Text] [Related]
18. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
19. [Study on the differences of two mouse models of hepatitis B virus infection by transduction with rAAV8-1. 3HBV].
Wang G; Dong XY; Tian WH; Yu CJ; Zheng G; Gao J; Wang GJ; Wei GC; Zhou YS; Wu XB
Bing Du Xue Bao; 2012 Sep; 28(5):541-7. PubMed ID: 23233931
[TBL] [Abstract][Full Text] [Related]
20. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
